Show simple item record

AuthorAbdul Q., Khan
AuthorAl-Tamimi, Maha
AuthorUddin, Shahab
AuthorSteinhoff, Martin
Available date2022-12-29T05:28:56Z
Publication Date2021-12-31
Publication NameDrug Discovery Today
Identifierhttp://dx.doi.org/10.1016/j.drudis.2021.07.006
ISSN13596446
URIhttps://www.sciencedirect.com/science/article/pii/S1359644621003147
URIhttp://hdl.handle.net/10576/37765
AbstractCancer is a complex heterogenic disease with significant therapeutic challenges. The presence of cancer stem cells (CSCs) in cancer tissue orchestrates tumor growth, progression, and metastasis, the tumor heterogeneity, disease relapse, and therapeutic resistance. Hence, it is imperative to explore how progenitor or cancer-initiating cells acquire stemness features and reprogram different biological mechanisms to maintain their sustained oncogenicity. Interestingly, deregulation of F-box proteins (FBPs) is crucial for cancer stemness features, including drug resistance and disease relapse. In this review, we highlight recent updates on the clinical significance of targeting FBPs in cancer therapy, with emphasis on eliminating CSCs and associated therapeutic challenges. Moreover, we also discuss novel strategies for the selective elimination of CSCs by targeting FBPs.
SponsorThis work was supported by IRGC-04-NI-17-155, IRGC-06-NI-19-189, and MRC-01-18-186, grants funded by the Medical Research Center (MRC), Hamad Medical Corporation, Doha, State of Qatar. The authors acknowledge open access funding provided by the Qatar National Library.
Languageen
PublisherElsevier
SubjectF-box proteins and signaling
Cancer pathogenesis
Cancer stem cells
Stemness
Poor clinical outcomes
TitleF-box proteins in cancer stemness: An emerging prognostic and therapeutic target
TypeArticle
Pagination2905-2914
Issue Number12
Volume Number26
Open Access user License http://creativecommons.org/licenses/by/4.0/
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record